Your fact-checks will appear here
The >90% efficacy estimates reported in licensing documents
The pivotal phase 3 ZOE-50 and ZOE-70 trials that supported SHINGRIX licensing were randomized, observer‑blind, placebo‑controlled studies — participants were assigned to receive two doses of the reco...
Two well-controlled phase 3 trials of the recombinant protein vaccine NVX‑CoV2373 showed high clinical efficacy for a two‑dose primary series — about 89.7% against symptomatic COVID‑19 in the UK trial...
Antibody kinetics after the first (prime) versus second (boost) vaccine dose follow a classic prime–boost pattern: the first dose elicits a slower, lower-magnitude antibody response that begins antige...
A small set of large, population‑level cohort studies and national register analyses have probed long‑term outcomes after routine childhood vaccination schedules, but the literature remains sparse and...